Sanofi CEO Chris Viehbacher has reviled the company's research site in Toulouse, France as unproductive and overly costly. But try as he may, he can't seem to rid himself and the company of the center and its 612 researchers, a move Viehbacher initially advocated as part of 2,500 job reduction plan in the mother country.
Sanofi can't shake the underproductive R&D site in Toulouse, France, without a fight from workers and French government officials. In the latest chapter of the ongoing feud, the Paris-based drug giant and a familiar critic in France's government show how far apart they stand on the fate of the research operation that brought the world the blood-thinner
India has started the countdown on new price controls for a vastly expanded list of drugs, a move that is expected to cut deeply into the profits of drugmakers for hundreds of drugs.
The pivotal study for SAR302503 nailed the primary endpoint for the proportion of patients with a greater than 35% reduction in the volume of their spleens, which become enlarged as a result of abnormal blood cell production.
Roche may be trying to unload its blood glucose meter business, reflecting continued challenges over reimbursement, and a contrast from the far better success the company has enjoyed with diagnostics development.
Sanofi has gone online in search of patients for clinical trials, partnering with the social network PatientsLikeMe and a healthcare nonprofit to inform patients about trials and match them with appropriate studies from the French drug giant.
The drugmaker has been fined by the French Competition Authority for "disparaging" generic copies of its now-off-patent bloodthinner, Plavix.
Alnylam Pharmaceuticals CEO John Maraganore has joined Third Rock in the advisory role of venture partner, reunited in a way with his former Millennium Pharmaceuticals colleagues who launched the venture firm 6 years ago.
The World Health Organization (WHO) has cleared the way for artemisinin-combination therapy (ACT) manufacturers to use Sanofi's semi-synthetic active ingredient. WHO acceptance comes one month after Sanofi began producing the active as an alternative to plant-derived artemisinin.
In 1977, dengue fever experts predicted a vaccine could be ready in 10 years. That prediction proved wildly optimistic, leaving the 2.5 billion people at risk from dengue fever without protection. Sanofi is at the forefront of dengue vaccine research but now faces a challenger from Japan.